Practice-based research networks (PBRNs) are organizations of clinicians working in practices that engage in research. PBRNs have emerged as a vital lynchpin in efforts to translate research into practice by translating practice into research. However, the development and maintenance and the continued engagement of busy community practices in cancer research requires specialized expertise and ongoing support. Therefore, the mission of the PBRN Core Facility is: ? To develop and sustain practice-based research networks that engage in cancer research; ? To advise and assist Case Comprehensive Cancer Center (Case CCC) investigators in developing community-based cancer research studies for implementation in PBRNs; ? To provide infrastructure that supports the implementation of Case CCC investigators'research studies in PBRNs, and that supports network practice-initiated research. The Practice-Based Research Network Core Facility supports the engagement of patients, clinicians, practices, and health systems in cancer research by: 1. Starting new PBRNs; 2. Developing the infrastructure of existing PBRNs; 3. Providing PBRN methods consultations to Cancer Center investigators and participating practices; 4. Advising and assisting investigators on research project implementation in PBRNs. The PBRN Core has started and sustained 8 successful PBRNs and is developing 5 new PBRNs. The established PBRNs represent major healthcare systems and include family medicine practices, federallyqualified health centers, community oncology practices, pediatrics practices, and general dentistry practices. The PBRN Core has facilitated the development and implementation of 23 funded research projects within the PBRNs that it has developed and sustained. Fourteen of these projects have been funded by NCI, and 6 supported by ACS. Grant funding for these projects totals over $15 million. The demand for the PBRN Core's services is strong and growing, and the potential for continued and expanded use of the facility is excellent. At present, 19 members of the Case CCC are pursuing 15 different lines of inquiry likely to result in funded studies to be implemented in Core-supported PBRNs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-20
Application #
7799316
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
20
Fiscal Year
2009
Total Cost
$137,662
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279
Bosca, Federica; Bielecki, Peter A; Exner, Agata A et al. (2018) Porphyrin-Loaded Pluronic Nanobubbles: A New US-Activated Agent for Future Theranostic Applications. Bioconjug Chem 29:234-240
Benson, Bryan L; Li, Lucy; Myers, Jay T et al. (2018) Biomimetic post-capillary venule expansions for leukocyte adhesion studies. Sci Rep 8:9328

Showing the most recent 10 out of 1227 publications